

PRA Health Sciences Inc

Ticker: PRAH

Country: US

Currency: USD Exchange: NSQ

Industry: Biotechnology & Medical Research

Buy

	Current (\$)	1W (\$)	1W (%)	LW (\$)
Close price	41.40	6.36 ▲	18.15 %	35.04
Target price	46.27	-0.26 ▼	-0.55 %	46.53

PRA Health Sciences, Inc. is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. It offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. The Company performs an array of services across the spectrum of clinical development programs, from the filing of investigational new drug (INDs) and similar regulatory applications to conducting all phases of clinical trials. Its service offerings include Product Registration Services, which includes Phase IIb through III product registration trials and Phase IV trials, inclusive of post-marketing commitments and registries; Strategic Solutions, which provides Embedded Solutions and functional outsourcing services, and Early Development Services, which includes Phase I through Phase IIa clinical trials and bioanalytical laboratory services.



Ratios	This week	Last week
Close price	41.40 ▲	35.04
High	41.98 ▲	35.42
Low	40.86 ▲	33.94
Beta	- -	-
Market cap	2,493 M ▲	2,108 M
Volume	- -	-
P/S ratio	1.70 x ▲	1.44 x
P/E ratio	- -	-
P/B ratio	3.65 x ▲	3.09 x
DPS yield	- -	-
EV/EBITDA	- -	-

(Unit : \$)

Headline

Created at	Type	Title
2015/11/02	reuters.com	BRIEF-PRA Health Sciences posts Q3 earnings \$0.37/shr

Rating and Target Price

(Unit : \$)

Target price		
Buy	46.27	
Last week		
Valuation analysis	Undervalued	Undervalued
Target price	49.37	49.24
Analysts consensus	Outperform	Outperform
Target price	44.41	44.91
Retail consensus	-	-
Target price	-	-

Analyst projections(2015)


(Unit : \$)

	Consensus	vs.LFY	High	Low	Participants
Revenue	1,365 M	-6.42 %	1,368 M	1,352 M	8
EPS	1.90	+737.01 %	1.92	1.84	9
DPS	0.00	-	0.00	0.00	3

Income Statement Summary

(Unit : \$)

	2010	2011	2012	2013	2014
Revenue	519 M	634 M	699 M	991 M	1,459 M
Operating income	47 M	55 M	35 M	-62 M	31 M
Net income	-0 M	17 M	-2 M	-88 M	-35 M



The company profile, other company-related information, analysts' opinion and projections in this Report are supplied by Thomson Reuters. This Report is intended to be used for information and reference purposes only, and does not constitute a solicitation, or an offer to make an investment in, or to purchase or sell, any specific investment products. The information in this Report may contain projections, opinions, assumptions, estimates and forecasts relating to future business performance and events. Minkabu Group makes no warranty regarding the accuracy or reliability of such projections, opinions, assumptions, estimates or forecasts, and has no liability for any damage of any kind arising out of reliance on such information. For more details, please refer to the Disclaimer on the last page of this Report.

PRA Health Sciences Inc

Ticker: PRAH Exchange: NSQ

Valuation analysis

Undervalued	based on	Target price	Potential	(Last week)	Undervalued	based on	Target price
	P/S ratio	49.37 \$	+19.25 %			P/S ratio	49.24 \$

Overall results

PRA Health Sciences Inc is considered overvalued based on its historical comparison analysis (KPI: P/S ratio), but considered undervalued based on its peer comparison analysis (KPI: EV/EBITDA multiple). But the historical comparison shows a higher correlation with the stock price of PRA Health Sciences Inc. As a result, this stock is considered

'undervalued'. However PRA Health Sciences Inc would be considered 'overvalued' if its price exceeded 49.37 \$. Disclaimer: The fact that PRA Health Sciences Inc is considered "undervalued" by the analysis does not mean that its price will rise in the future. Monitor the sales of PRA Health Sciences Inc closely and keep an eye on its external environment to support your investment decision.

Recent figures (3 months)

(Unit : \$)

	Curr.	Ø	Max.	Min.
Price	41.40	39.59	45.44	33.98
Volume	359,125	225,800	585,953	57,527
Market cap	2,493 M	2,379 M	2,733 M	2,044 M

		Sales (P/S ratio)	Profit (P/E ratio)	BookValue (P/B ratio)	Dividend (DPS yield)	Cash-flow (EV/EBITDA)
Valuation analysis		1.70 x	-	3.65 x	-	-
Historical comparison	Result	overvalued		overvalued		undervalued
	Average	1.45 x	-	3.07 x	-	183.74 x
	Importance	High	Low	Low	Low	Low
Peer comparison	Result	overvalued		undervalued		undervalued
	Average	2.79 x	-	6.54 x	-	18.78 x
	Adjusted	1.64 x	-	6.54 x	-	183.74 x
	Correlation	0.43	-	0.52	-	0.83
	Comparison					
	Importance	Low	Low	Low	Low	High

Historical comparison


Currently, PRA Health Sciences Inc is considered 'overvalued' by the analysis because its P/S ratio is higher than its historical average.

Peer comparison

On the other hand, the EV/EBITDA multiple of this stock tends to have a high correlation with the average of domestic companies with similar market capitalization. As a result, many investors may estimate the trend of its cash flow based investment return by comparing the company with domestic companies with similar market capitalization. And PRA Health Sciences Inc tended to trade at a premium in the past compared to its peers. As a result, this stock is considered 'undervalued' based on a peer comparison.

Analysts consensus

Outperform	Target price	Potential	(Last week)	Outperform	Target price
	44.41 \$	+7.27 %			44.91 \$



Valuation

Based on analyst projections

	Consensus	Low	High	Domestic(Ø)	Global(Ø)
PSR	1.82 x	1.80 x	1.82 x	149.94 x	128.55 x
PER	21.75 x	21.56 x	22.50 x	30.15 x	54.88 x

Based on last year's results

	PRA Health Sciences Inc	Domestic(Ø)	Global(Ø)
P/S ratio	1.70 x	13.59 x	14.29 x
P/E ratio	-	32.91 x	63.85 x

PRA Health Sciences Inc

Ticker: PRAH Exchange: NSQ

Industry average (domestic): Biotechnology & Medical Research w/Top 3 market cap


Rating & Valuation

(Unit : \$)

		PRA Health Sciences Inc	Gilead Sciences Inc [GILD/US]	Amgen Inc [AMGN/US]	Celgene Corp [CELG/US]	Domestic(Ø)
Close price		41.40	108.34	160.46	116.74	-
Valuation analysis	Rating	Undervalued	Undervalued	Undervalued	Overvalued	-
	Target price	49.37	119.70	165.25	109.53	-
	Potential	+19.26 %	+10.48 %	+2.98 %	-6.16 %	-
Analysts consensus	Rating	Outperform	Outperform	Outperform	Outperform	-
	Target price	44.41	125.31	186.33	146.12	-
	Potential	+7.28 %	+15.66 %	+16.12 %	+25.17 %	-
Retail consensus	Rating	-	-	-	-	-
	Target price	-	-	-	-	-
	Potential	-	-	-	-	-
Market cap		2,493 M	156,137 M	121,039 M	91,717 M	834 M
EnterpriseValue		3,357 M	158,413 M	124,728 M	91,042 M	826 M
P/E ratio	last FY (norm.)	-	14.74 x	22.43 x	47.71 x	32.91 x
	projected	21.75 x	8.87 x	15.90 x	24.15 x	30.15 x
PSR	last FY	1.70 x	6.27 x	6.03 x	11.95 x	13.59 x
	projected	1.82 x	4.85 x	5.59 x	9.93 x	149.94 x
EV/EBITDA(LFT)		20.51 x	9.70 x	14.40 x	30.95 x	23.99 x

Fundamentals

		PRA Health Sciences Inc	Gilead Sciences Inc	Amgen Inc	Celgene Corp	Domestic(Ø)
Sales	last FY	1,459 M	24,890 M	20,063 M	7,670 M	96 M
	projected	1,365 M	32,130 M	21,619 M	9,234 M	100 M
	vs last FY	-6.42 %	+29.08 %	+7.75 %	+20.39 %	-
Income before tax	last FY	-41 M	14,856 M	5,585 M	2,327 M	165 M
	projected	166 M	-	-	-	66 M
	vs last FY	-	-	-	-	-
EBITDA(LFY)		163 M	16,315 M	8,660 M	2,941 M	197 M
Book value(LFY)		676 M	15,426 M	25,778 M	6,524 M	97 M



The company profile, other company-related information, analysts' opinion and projections in this Report are supplied by Thomson Reuters. This Report is intended to be used for information and reference purposes only, and does not constitute a solicitation, or an offer to make an investment in, or to purchase or sell, any specific investment products. The information in this Report may contain projections, opinions, assumptions, estimates and forecasts relating to future business performance and events. Minkabu Group makes no warranty regarding the accuracy or reliability of such projections, opinions, assumptions, estimates or forecasts, and has no liability for any damage of any kind arising out of reliance on such information. For more details, please refer to the Disclaimer on the last page of this Report.

PRA Health Sciences Inc

Ticker: PRAH Exchange: NSQ

Industry average (worldwide): Biotechnology & Medical Research Market cap Top3


Rating & Valuation

(Unit : \$)

		PRA Health Sciences Inc	Gilead Sciences Inc [GILD/US]	Amgen Inc [AMGN/US]	Celgene Corp [CELG/US]	Global(Ø)
Close price		41.40	108.34	160.46	116.74	-
Valuation analysis	Rating	Undervalued	Undervalued	Undervalued	Overvalued	-
	Target price	49.37	119.70	165.25	109.53	-
	Potential	+19.26 %	+10.48 %	+2.98 %	-6.16 %	-
Analysts consensus	Rating	Outperform	Outperform	Outperform	Outperform	-
	Target price	44.41	125.31	186.33	146.12	-
	Potential	+7.28 %	+15.66 %	+16.12 %	+25.17 %	-
Retail consensus	Rating	-	-	-	-	-
	Target price	-	-	-	-	-
	Potential	-	-	-	-	-
Market cap		2,493 M	156,137 M	121,039 M	91,717 M	760 M
EnterpriseValue		3,357 M	158,413 M	124,728 M	91,042 M	1,924 M
P/E ratio	last FY (norm.)	-	14.74 x	22.43 x	47.71 x	63.85 x
	projected	21.75 x	8.87 x	15.90 x	24.15 x	54.88 x
PSR	last FY	1.70 x	6.27 x	6.03 x	11.95 x	14.29 x
	projected	1.82 x	4.85 x	5.59 x	9.93 x	128.55 x
EV/EBITDA(LFT)		20.51 x	9.70 x	14.40 x	30.95 x	40.81 x

Fundamentals

		PRA Health Sciences Inc	Gilead Sciences Inc	Amgen Inc	Celgene Corp	Global(Ø)
Sales	last FY	1,459 M	24,890 M	20,063 M	7,670 M	90 M
	projected	1,365 M	32,130 M	21,619 M	9,234 M	87 M
	vs.LFY	-6.42 %	+29.08 %	+7.75 %	+20.39 %	-
Income before tax	last FY	-41 M	14,856 M	5,585 M	2,327 M	115 M
	projected	166 M	-	-	-	60 M
	vs.LFY	-	-	-	-	-
EBITDA(LFY)		163 M	16,315 M	8,660 M	2,941 M	130 M
Book value(LFY)		676 M	15,426 M	25,778 M	6,524 M	100 M



The company profile, other company-related information, analysts' opinion and projections in this Report are supplied by Thomson Reuters. This Report is intended to be used for information and reference purposes only, and does not constitute a solicitation, or an offer to make an investment in, or to purchases or sell, any specific investment products. The information in this Report may contain projections, opinions, assumptions, estimates and forecasts relating to future business performance and events. Minkabu Group makes no warranty regarding the accuracy or reliability of such projections, opinions, assumptions, estimates or forecasts, and has no liability for any damage of any kind arising out of reliance on such information. For more details, please refer to the Disclaimer on the last page of this Report.

PRA Health Sciences Inc

Ticker: PRAH Exchange: NSQ

Financials

Income statement

(Unit : M\$)

	2010	2011	2012	2013	2014
Revenue	519	634	699	991	1,459
Total revenue	519	634	699	991	1,459
Cost of revenue total	317	408	461	685	1,052
Gross profit	202	226	238	306	407
Selling general administrative expenses total	119	138	160	212	253
Depreciation amortization	35	32	30	50	96
Unusual expense income	0	0	11	105	25
Total operating expense	471	578	663	1,054	1,427
Operating income	47	55	35	-62	31
Interest income or expense net non operating	-41	-32	-40	-64	-71
Other net	-0	-0	0	0	-2
Income before tax	5	23	-4	-126	-41
Income tax total	5	5	-1	-39	-8
Income after tax	-0	17	-2	-87	-33
Equity in affiliates	0	0	0	-1	-2
Net income before extra items	-0	17	-2	-88	-35
Net income	-0	17	-2	-88	-35
Diluted net income	-0	17	-2	-88	-35
Income available to common excl extra items	-0	17	-2	-88	-35
Income available to common incl extra items	-0	17	-2	-88	-35
Diluted weighted average shares	57	57	57	57	42

Balance sheet summary

(Unit : M\$)

	2010	2011	2012	2013	2014
Cash and equivalents	-	-	109	72	85
Cash and short term investments	-	-	109	72	85
Accounts receivable trade net	-	-	184	294	338
Note receivable long term	-	-	5	0	-
Total receivables net	-	-	187	320	342
Prepaid expenses	-	-	18	27	33
Other current assets total	-	-	8	37	27
Total current assets	-	-	324	457	488
Property plant equipment total gross	-	-	112	81	101
Accumulated depreciation total	-	-	-61	-6	-28
Property plant equipment total net	-	-	50	75	72
Goodwill net	-	-	490	1,099	1,033
Intangibles net	-	-	108	699	600
Long term investments	-	-	0	3	1
Other long term assets total	-	-	2	58	40
Total assets	-	-	982	2,394	2,238
Accounts payable	-	-	17	27	39
Accrued expenses	-	-	61	108	109
Notes payable short term debt	-	-	0	10	0
Current port of lt debt capital leases	-	-	3	8	0
Other current liabilities total	-	-	223	314	318
Total current liabilities	-	-	305	469	466
Long term debt	-	-	451	1,245	948
Total long term debt	-	-	451	1,245	948
Deferred income tax	-	-	26	185	106


The company profile, other company-related information, analysts' opinion and projections in this Report are supplied by Thomson Reuters. This Report is intended to be used for information and reference purposes only, and does not constitute a solicitation, or an offer to make an investment in, or to purchase or sell, any specific investment products. The information in this Report may contain projections, opinions, assumptions, estimates and forecasts relating to future business performance and events. Minkabu Group makes no warranty regarding the accuracy or reliability of such projections, opinions, assumptions, estimates or forecasts, and has no liability for any damage of any kind arising out of reliance on such information. For more details, please refer to the Disclaimer on the last page of this Report.

Other liabilities total	-	-	22	26	40
Total liabilities	-	-	806	1,927	1,561
Additional paid in capital	-	-	330	490	821
Retained earnings or accumulated deficit	-	-	-156	-39	-75
Other equity total	-	-	2	16	-69
Total equity	-	-	175	467	676
Total liabilities and shareholders equity	-	-	982	2,394	2,238
Total debt	-	-	454	1,264	948

Cash flow summary

(Unit : M\$)

	2010	2011	2012	2013	2014
Net income starting line	-	-	-2	-88	-35
Depreciation depletion	-	-	30	50	96
Deferred taxes	-	-	-7	-51	-31
Non cash items	-	-	32	56	13
Cash interest paid	-	-	27	44	80
Cash taxes paid	-	-	14	4	6
Changes in working capital	-	-	46	57	-19
Cash from operating activities	-	-	99	25	22
Capital expenditures	-	-	-18	-19	-27
Other investing cash flow items total	-	-	0	-1,059	15
Cash from investing activities	-	-	-18	-1,079	-12
Total cash dividends paid	-	-	-101	-131	0
Issuance or retirement of stock net	-	-	0	470	333
Issuance or retirement of debt net	-	-	61	789	-318
Cash from financing activities	-	-	-42	1,077	8
Financing cash flow items	-	-	-1	-50	-6
Foreign exchange effects	-	-	0	-0	-5
Net change in cash	-	-	39	23	13



The company profile, other company-related information, analysts' opinion and projections in this Report are supplied by Thomson Reuters. This Report is intended to be used for information and reference purposes only, and does not constitute a solicitation, or an offer to make an investment in, or to purchase or sell, any specific investment products. The information in this Report may contain projections, opinions, assumptions, estimates and forecasts relating to future business performance and events. Minkabu Group makes no warranty regarding the accuracy or reliability of such projections, opinions, assumptions, estimates or forecasts, and has no liability for any damage of any kind arising out of reliance on such information. For more details, please refer to the Disclaimer on the last page of this Report.

PRA Health Sciences Inc

Ticker: PRAH Exchange: NSQ

Corporate profile

Company profile

Business summary	PRA Health Sciences, Inc. is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. It offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. The Company performs an array of services across the spectrum of clinical development programs, from the filing of investigational new drug (INDs) and similar regulatory applications to conducting all phases of clinical trials. Its service offerings include Product Registration Services, which includes Phase IIb through III product registration trials and Phase IV trials, inclusive of post-marketing commitments and registries; Strategic Solutions, which provides Embedded Solutions and functional outsourcing services, and Early Development Services, which includes Phase I through Phase IIa clinical trials and bioanalytical laboratory services.
Financial summary	BRIEF: For the nine months ended 30 September 2015, PRA Health Sciences Inc revenues increased 9% to \$1.18B. Net income totaled \$53.3M vs. loss of \$12.9M. Revenues reflect Service Revenue increase of 8% to \$1.01B, Reimbursement Revenue increase of 17% to \$171.4M. Net Income reflects Selling, General and Administrative decrease of 34% to \$118.1M (expense), Depreciation and Amortization decrease of 73% to \$19.8M (expense), Interest Expense.
Homepage	http://www.prahs.com/
Address	4130 Parklake Ave Ste 400 RALEIGH NC
Public contact	
Phone number	1-919-7868200
Contact phone number	
Contact email	

Management

Rank	Name	Position	Since	Age
1	Colin Shannon	Chairman of the Board, President, Chief Executive Officer	2014	54
2	Linda Baddour	Chief Financial Officer, Executive Vice President	2014	56
3	David W. Dockhorn	Executive Vice President, Chief Compliance Officer	2014	53

On December 31, 2014 PRA Health Sciences Inc had 11,000 Employees.

The company profile, other company-related information, analysts' opinion and projections in this Report are supplied by Thomson Reuters. This Report is intended to be used for information and reference purposes only, and does not constitute a solicitation, or an offer to make an investment in, or to purchase or sell, any specific investment products. The information in this Report may contain projections, opinions, assumptions, estimates and forecasts relating to future business performance and events. Minkabu Group makes no warranty regarding the accuracy or reliability of such projections, opinions, assumptions, estimates or forecasts, and has no liability for any damage of any kind arising out of reliance on such information. For more details, please refer to the Disclaimer on the last page of this Report.

PRA Health Sciences Inc

Ticker: PRAH Exchange: NSQ

Historical Charts

M3 Chart



Historical data

(Unit : \$)

	High	Low	Volume
2015/08/10 -	43.44	40.05	835,299
2015/08/17 -	42.73	38.01	1,124,578
2015/08/24 -	38.54	33.74	970,162
2015/08/31 -	39.41	36.86	749,251
2015/09/07 -	41.38	39.01	500,326
2015/09/14 -	46.35	40.75	1,112,199
2015/09/21 -	45.69	40.80	1,465,160
2015/09/28 -	41.38	37.26	1,560,683
2015/10/05 -	41.85	37.28	938,121
2015/10/12 -	40.44	37.40	1,047,833
2015/10/19 -	41.94	33.00	1,498,469
2015/10/26 -	36.96	33.94	1,053,975
During	46.35	33.00	-

Y1 Chart




Historical data

(Unit : \$)

	High	Low	Volume
2014/12/01 -	26.97	21.01	8,653,236
2015/01/01 -	28.15	22.40	4,076,016
2015/02/01 -	31.99	26.01	3,257,248
2015/03/01 -	31.90	27.61	5,464,012
2015/04/01 -	30.64	26.91	2,709,423
2015/05/01 -	33.96	28.27	5,785,652
2015/06/01 -	37.41	33.31	3,751,200
2015/07/01 -	44.01	35.22	3,246,438
2015/08/01 -	43.44	33.74	4,009,997
2015/09/01 -	46.35	36.86	4,848,075
2015/10/01 -	41.94	33.00	4,959,459
During	46.35	21.01	-

Y5 Chart



The company profile, other company-related information, analysts' opinion and projections in this Report are supplied by Thomson Reuters. This Report is intended to be used for information and reference purposes only, and does not constitute a solicitation, or an offer to make an investment in, or to purchases or sell, any specific investment products. The information in this Report may contain projections, opinions, assumptions, estimates and forecasts relating to future business performance and events. Minkabu Group makes no warranty regarding the accuracy or reliability of such projections, opinions, assumptions, estimates or forecasts, and has no liability for any damage of any kind arising out of reliance on such information. For more details, please refer to the Disclaimer on the last page of this Report.

PRA Health Sciences Inc

Ticker: PRAH Exchange: NSQ

Disclaimer

This Report (this "Report") is prepared by Minkabu, Inc. and its subsidiary, sharewise GmbH (collectively, "Minkabu Group") based on information supplied by a third party service provider, namely Thomson Reuters.

The company profile, other company-related information, analysts' opinions and projections in this Report are supplied by Thomson Reuters. Stock and index prices are supplied by Stock Exchanges of Tradegate Exchange, Euronext, Deutsche Börse AG, BME, Stuttgart Stock Exchange, Tradegate Exchange, BATS CHI-X Europe, London Stock Exchange, NASDAQ Stock Market, Indonesia Stock Exchange, Singapore Exchange, Hong Kong Exchanges and Clearing Limited, Taiwan Stock Exchange, Tokyo Stock Exchange, Nagoya Stock Exchange, Toronto Stock Exchange, Shenzhen Stock Exchange, Shanghai Stock Exchange, SIX Swiss Exchange, BM&FBOVESPA S.A, DotEx. HKEX INFORMATION SERVICES LIMITED, ITS HOLDING COMPANIES AND/OR ANY SUBSIDIARIES OF SUCH HOLDING COMPANIES ENDEAVOUR TO ENSURE THE ACCURACY AND RELIABILITY OF THE INFORMATION PROVIDED BUT DO NOT GUARANTEE ITS ACCURACY OR RELIABILITY AND ACCEPT NO LIABILITY (WHETHER IN TORT OR CONTRACT OR OTHERWISE) FOR ANY LOSS OR DAMAGE ARISING FROM ANY INACCURACIES OR OMISSIONS. Any expressions of opinions by analysts are solely the personal opinions of the authors and contributors to this Report. Minkabu Group is not responsible for accuracy, completeness, reliability or timeliness for these information and opinions, and is not responsible for any errors or omissions therein, and assumes no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of your reliance on such information or the use of this Report.

The information in this Report may contain projections, opinions, assumptions, estimates and forecasts relating to future business performance and events, which are intended as examples only, and do not represent predictions by Minkabu Group about the current or future performance of any company or its securities, or any investment products. Minkabu Group makes no warranty regarding the accuracy or reliability of such projections, opinions, assumptions, estimates or forecasts, and has no liability for any damage of any kind arising out of reliance on such information. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual results may differ from those in forward-looking statements as a result of various factors. Minkabu Group is not obligated to update or correct any such information.

This Report does not constitute a recommendation to make an investment in, or to purchase or sell any specific investment products. This Report is not intended to give financial or investment advice. You should conduct your own careful, independent analysis or seek advice from professional advisor as to the suitability of an investment for your needs.

Minkabu Group does not express any opinion on any company or its securities, or any investment products (or any fluctuations in or future performance thereof), and stock price ratings and comments including "Target Price", "Buy", "Sell", or "Hold" are created by an aggregation of opinions from individual investors, or from opinions of analysts of securities companies.

Ratings such as "Overvalued", "Undervalued" or "Fairlyvalued", and "Fair Stock Prices" and others displayed ancillary to ratings are objective facts based on the statistical record, and Minkabu Group does not express any opinion on any company or its securities, or any investment products (or any fluctuations in or future performance thereof) thereby either.

Minkabu Group does not represent or warrant that this Report is appropriate or available for viewing or downloading at any location. You are exclusively responsible for compliance with all applicable local laws and regulations in viewing or downloading this Report.

This Report is intended to be used for information and reference purposes only, and does not constitute a solicitation, or an offer to make an investment in, or to purchase or sell, any specific investment products. Minkabu Group is not a registered broker, dealer, investment advisor, analyst, investment banker or underwriter.

Minkabu Group may hold the securities referred to in this Report including derivative instruments, or may have business relations with the companies discussed herein.

Without prior written consent of Minkabu Group, no reproduction, copy, transmission, transfer, distribution, publication, or any other similar actions of any content of this Report shall be made.